Reata Pharmaceuticals, Inc. (RETA)
| Market Cap | 991.06M |
| Revenue (ttm) | 11.46M |
| Net Income (ttm) | -303.77M |
| Shares Out | 36.46M |
| EPS (ttm) | -8.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 490,406 |
| Open | 26.56 |
| Previous Close | 27.84 |
| Day's Range | 26.39 - 28.22 |
| 52-Week Range | 20.24 - 153.41 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 60.86 (+123.9%) |
| Earnings Date | May 10, 2022 |
About RETA
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ...
Financial Performance
In 2021, RETA's revenue was $11.49 million, an increase of 27.40% compared to the previous year's $9.02 million. Losses were -$297.39 million, 20.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for RETA stock is "Buy." The 12-month stock price forecast is 60.86, which is an increase of 123.91% from the latest price.
News
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4
Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Develop...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results fo...
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Devel...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report ...
Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same.
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Pat...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the completion of t...
Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further str...
Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - March 15, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals,...
Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y
Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.
Reata Pharmaceuticals, Inc. (RETA) Reports Q4 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the ...
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on C...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results fo...
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients wi...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Resp...
Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q4 Earnings Expected to Decline
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp....
FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses Over...
New York, New York--(Newsfile Corp. - February 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betw...
RETA SHAREHOLDER ALERT: Jakubowitz Law Reminds Reata Shareholders of a Lead Plaintiff Deadline of February 18, 2022
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA). To re...
RETA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Coun...
NEW YORK , Feb. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 20...
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report ...
Reata Class Action Reminder
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp....
RETA INVESTOR ALERT: Thornton Law Firm Reminds Reata Pharmaceuticals Investors of Important Deadline for Securities C...
Boston, Massachusetts--(Newsfile Corp. - February 17, 2022) - The Thornton Law Firm reminds investors that a class action lawsuit has been filed on behalf of investors of Reata Pharmaceuticals, Inc. (NA...
RETA INVESTOR DEADLINE TOMRROW: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Inve...
San Francisco, California--(Newsfile Corp. - February 17, 2022) - Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securitie...
Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,...
Los Angeles, California--(Newsfile Corp. - February 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reata Pharmaceutic...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Phar...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 18, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investo...